|
Seegene Study Concludes That Multi-Pathogen Diagnostics Are Critical for Accurately Diagnosing Infectious Diseases
(Market Wire Via Thomson Dialog NewsEdge) ROCKVILLE, MD, October 23 / MARKET WIRE/ --
Seegene today made public the results of
several clinical studies seeking to measure the rate of accurately
diagnosing sexually transmitted diseases (STDs) and respiratory virus (RV)
infections among infected populations. The studies carried out in Korea and
Japan compared conventional single-pathogen tests against Seegene's
simultaneous multi-pathogen test systems. The results effectively conclude
that conventional testing regimens relying on single pathogen tests leave
an alarmingly high percentage of patient infections undiagnosed.
Highlights of the results conclude that:
-- A large percentage of respiratory
infections go undiagnosed: From a
pool of 903 respiratory patient
samples, an astounding 72% tested
positive for a RV infection when
monitored by Seegene's 12-plex
multi-RV detection system. Using
a conventional single RV
detection system those same 903
patient samples yielded only a 5%
positive infection rate of
influenza A, 8% for influenza B,
16% of Respiratory Syncytial
Virus (RSV) A, and 14% of RSV B.
-- A large percentage of sexually
transmitted diseases (STDs) go
undiagnosed: From a pool of 673
STD patient samples, Seegene's
6-plex multi-STD detection
system yielded an STD infection rate of 81%, and a co-
infection (two or more pathogens) rate of 24%. With conventional routine
testing for Chlamydia trachomatis and Neisseria gonorrhoeae, only 16% and
5% of the respective infections were detected.
At the recent 11th Asian Pacific Congress of Clinical Biochemistry (APCCB),
Dr. Chang-Seok Ki of Samsung Medical Center and Sungkyunkwan University
School of Medicine in Seoul, Korea, who performed the RV study, said, "The
Seeplex multiplex-PCR assay is a viable alternative to conventional
VC/IF-based test methods, making it a suitable diagnostic modality for
respiratory disease."
Dr. Ki added, "Additionally, the Seeplex system achieves its sensitivity
within 24 hours compared to a viral culture can take up to a week. Our data
suggests that Seeplex tests will help reduce the incidence of nosocomial
transmission to high risk patients, and improve the clinical management
through the use of appropriate and directed treatment after diagnosis."
Jong-Yoon Chun, Founder and Chief Executive Officer, Seegene, stated, "The
result of these studies, carried out by a world-class consortium of
hospitals, is clear: only a multi-pathogen detection system like Seegene's
is able to correctly diagnose a wide range of infectious diseases
accurately, as well as simultaneously. Without Seegene too many diseases
risk going undetected with potentially disastrous results for patients."
Seegene recently announced its Seeplex 18-plex Respiratory Pathogen
Test, which today is the only diagnostic test capable of simultaneously
detecting 18 of the most prevalent respiratory infections -- both virus and
bacteria born -- in a single test. The Seeplex 18-plex Respiratory
Pathogen Test detects 11 different respiratory RNA viruses, 2 DNA viruses,
and 5 pneumonia bacteria from samples including nasopharyngeal aspirates,
nasopharyngeal swabs and bronchoalveolar lavage.
Seeplex tests are based on Dual Priming Oligo (DPO) for blocking extension
of non-specific primed templates, thereby generating consistently high PCR
specificity even under less than optimal PCR conditions.
The RV infection study was carried by the Samsung Medical Center, Inje
University College of Medicine Sanggye-Paik Hospital, Korea University Anam
Hospital, Korea University Guro Hospital and Dankook University. The STD
infection study was carried out by the Chung-Ang University Young-San
Hospital, Eone Reference Laboratory in Korea, and Leisure, Inc. in Japan.
About Seegene
Seegene, Inc. is pioneering the field of
multi-pathogen testing. Seegene applies its novel and proprietary Seeplex
system utilizing "DPO (Dual Priming Oligo)" and "ACP (Annealing Control
Primer)" to create multi-pathogen tests delivering maximum specificity,
reproducibility and sensitivity. With over 260 citations and several
patents and patents pending, Seegene has been offering advanced molecular
diagnostics services to over 1,000 major global institutes in more than 25
countries. Seegene is actively working with both the scientific and OEM
business community. Seegene's mission is to integrate Seeplex with disease
diagnostics to provide a new guideline for effectively treating patients.
Seegene was founded in 2000 and is based in Rockville, MD and Seoul, Korea.
For more information please visit www.seegene.com.
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=608607
Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=608609
Contacts:
Jessica Joung
Seegene Inc.
301-762-9066Email Contact
or
Constantine Theodoropulos
Boston Communications
617-292-7319Email Contact
Copyright 2007 Market Wire, Incorporated
[ Back To Smart Product Home's Homepage ]
|